TritonPoint Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

TritonPoint Wealth’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$583K	Buy	769 +24	+3%	+$18.1K	0.06%	162
2026 Q2	$465K	Buy	745 +64	+9%	+$43.6K	0.05%	184
2026 Q1	$526K	Sell	681 -148	-18%	-$113K	0.06%	165
2025 Q4	$640K	Sell	829 -1,938	-70%	-$1.32M	0.06%	152
2025 Q3	$1.56M	Buy	2,767 +281	+11%	+$159K	0.13%	125
2025 Q2	$1.3M	Sell	2,486 -69	-3%	-$38.5K	0.12%	136
2025 Q1	$1.62M	Sell	2,555 -4	-0.2%	-$2.75K	0.15%	127
2024 Q4	$1.82M	Sell	2,559 -145	-5%	-$122K	0.17%	119
2024 Q3	$2.82M	Buy	2,704 +148	+6%	+$165K	0.26%	95
2024 Q2	$2.69M	Buy	2,556 +92	+4%	+$89.2K	0.26%	90
2024 Q1	$1.92M	Buy	2,464 +206	+9%	+$196K	0.2%	108
2023 Q4	$1.98M	Buy	+2,258	New	+$1.86M	0.19%	112

Other funds holding REGN

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

TritonPoint Wealth's REGN Position: Q3 2026 in Review

TritonPoint Wealth increased its Regeneron Pharmaceuticals (REGN) stake by 3.2% in Q3 2026, buying an estimated $18.1K and bringing the position to 769 shares worth $583K. The position accounts for 0.06% of the portfolio, ranked #162.

TritonPoint Wealth first reported a position in REGN in Q4 2023 and has held it in 12 quarters since. The position peaked at $2.82M in Q3 2024. 1,212 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

TritonPoint Wealth held 769 shares of Regeneron Pharmaceuticals worth $583K as of Q3 2026.
TritonPoint Wealth bought 24 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $18.1K.
Regeneron Pharmaceuticals made up 0.06% of TritonPoint Wealth's portfolio in Q3 2026, its #162 holding.
TritonPoint Wealth first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
TritonPoint Wealth's Regeneron Pharmaceuticals position peaked at $2.82M in Q3 2024.
1,212 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on TritonPoint Wealth's 13F filing for Q3 2026, filed 19 Oct 2026.